Fennec Pharmaceuticals Inc (TSX:FRX)
C$ 5.98 -0.1 (-1.64%) Market Cap: 163.64 Mil Enterprise Value: 148.01 Mil PE Ratio: 115.00 PB Ratio: 0 GF Score: 32/100

Q4 2023 Fennec Pharmaceuticals Inc Earnings Call Transcript

Mar 21, 2024 / 12:30PM GMT
Release Date Price: C$13.18
Operator

Good morning, ladies and gentlemen, and welcome to the Fennec Pharmaceuticals fourth-quarter and full year 2023 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference is being recorded.

Now I would like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade. You may begin.

Robert Andrade
Fennec Pharmaceuticals Inc. - CFO

Thank you, operator, and good morning, everyone. We appreciate you joining us today for Fennec Pharmaceuticals' fourth quarter and full year 2023 earnings conference call, during which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning are Rosty Raykov, our Chief Executive Officer, and Adrian Haigh, our Chief Operating Officer.

Before we begin, I would like to remind you that during this call the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot